Third-look endoscopy prevents delayed bleeding after endoscopic submucosal dissection under antithrombotic therapy

Table 3 Baseline characteristics of the third-look endoscopy and control group before propensity score matching

	TLE (n = 114)	Control (n = 132)	P value
Age, mean ± SD (yr)	75.5 ± 6.2	76.2 ± 6.5	0.37
Sex			0.68
Male, % (n)	86.0 (98)	84.1 (111)
Female, % (n)	14.0 (16)	15.9 (21)
Location-1			0.51
Upper, % (n)	18.4 (21)	15.2 (20)
Middle, % (n)	12.3 (14)	13.6 (18)
Lower, % (n)	69.3 (79)	71.2 (94)
Location-2			0.005
Anterior wall, % (n)	8.8 (10)	25.0 (33)
Posterior wall, % (n)	31.6 (36)	19.7 (26)
Lesser curvature, % (n)	40.4 (46)	37.9 (50)
Greater curvature, % (n)	19.3 (22)	17.4 (23)
Morphology			0.53
Protruded, % (n)	43.0 (49)	47.0 (62)
Flat/depressed, % (n)	57.0 (65)	53.0 (70)
Median tumor size (range)	11.0 (2-70)	12.0 (3-60)	0.77
Median specimen size (range)	35.0 (18-95)	35.0 (15-97)	0.89
Ulcerative findings			0.79
(+), % (n)	5.3 (6)	4.6 (6)
(-), % (n)	94.7 (108)	95.5 (126)
Depth of invasion			0.09
M/SM1, % (n)	98.3 (112)	93.9 (124)
SM2-, % (n)	1.8 (2)	6.1 (8)
Pathological finding			0.07
Differentiated type, % (n)	95.6 (109)	99.2 (131)
Undifferentiated type, % (n)	4.4 (5)	0.8 (1)
Lymphovascular infiltration			0.74
(+), % (n)	4.4 (5)	5.3 (7)
(-), % (n)	95.6 (109)	94.7 (125)
Median procedure time (range)	41.5 (10-180)	42.0 (7-215)	0.84
Receiving antithrombotic agents			< 0.0001
Continue, % (n)	100 (114)	43.9 (58)
Discontinue, % (n)	0 (0)	56.1 (74)

TLE: Third-look endoscopy; M: Mucosa; SM1: Submucosa (-500 μm); SM2-: Submucosa (500 μm-).